Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

June 30, 2027

Conditions
Severe Aplastic AnemiaCyclophosphamide Reduced-doseImmunosuppressive Therapy
Interventions
DRUG

Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy

Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.

Trial Locations (1)

301617

RECRUITING

Red Blood Cell Disorders Center and Regenerative Medicine Center, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER